Posters

Sustained-delivery fluocinolone acetonide intravitreal implant for diabetic macular oedema: 2 year results

Poster Details

First Author: N.Arruti UK

Co Author(s):    R. Alieldin   A. Hawrami   H. Zambarakji   S. Patra                    

Abstract Details



Purpose:

To assess the efficacy and safety of fluocinolone acetonide intravitreal implant (Iluvien®) in patients with diabetic macular oedema (DMO).

Setting:

Retrospective study of all the patients who received a fluocinolone acetonide intravitreal implant between the years 2014 and 2017 at Whipps Cross University Hospital (London).

Methods:

41 subjects previously diagnosed with DMO received the Iluvien® implant between January 2014 and February 2017. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed at baseline, 2-4 weeks, 3 months, 1 year and 2 years.

Results:

All our patients were examined at baseline and at 2-4 weeks. The mean BCVA at baseline was 0.60 LogMAR (SD ± 0.25) and the mean CMT was 459 microns (SD ± 118.6). At 2-4 weeks, the mean BCVA remained unchanged and the mean CMT was 403 microns (SD ± 84 microns). At the 3 month visit 33 patients were examined. The mean BCVA improved to 0.55 LogMAR (SD ± 0.27) with a further reduction on the CMT (mean 392 microns, SD ± 100). One year after receiving the implant, 31 patients were examined. The BCVA continue to improve, with a mean of 0.54 LogMAR (SD ± 0.26) and a stable CMT (mean 394 microns, SD ± 116.6) was found. A total of 18 patients have been followed up for 2 years, showing a mean BCVA of 0.59 LogMAR (SD ± 0.3) and mean CMT of 421 microns (SD ± 82). Increase in intraocular pressure occurred in 24% patients, successfully controlled with topical treatment in all of them. During the 2 years period, 3 of our patients deceased.

Conclusions:

Fluocinolone acetonide intravitreal implant improved BCVA in patients with DMO over the first year with a significant reduction of the CMT. At year 2, our data suggest a trend towards baseline in both BCVA and CMT. The number of subjects requiring glaucoma treatment after the implant remained low.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy